ZYUS:CA:TSV-ZYUS Life Sciences Corporation (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1

Change

0.00 (0.00)%

Market Cap

USD 0.07B

Volume

500.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

+0.26 (+3.16%)

USD 0.10B
LOVE:CA Cannara Biotech Inc

+0.03 (+3.90%)

USD 0.07B
LSL:CA LSL Pharma Group Inc.

+0.02 (+4.26%)

USD 0.05B
DB:CA Decibel Cannabis Company Inc

N/A

USD 0.05B
SBBC:CA Simply Better Brands Corp

+0.04 (+8.05%)

USD 0.03B
PCLO:CA Pharmacielo Ltd

N/A

USD 0.03B
ROMJ:CA Rubicon Organics Inc

-0.17 (-30.00%)

USD 0.02B
CANB:CA CanadaBis Capital Inc

+0.01 (+5.26%)

USD 0.01B
ELXR:CA Elixxer Ltd

N/A

USD 0.01B
NDVA:CA Indiva Ltd

+0.01 (+8.33%)

USD 0.01B

ETFs Containing ZYUS:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.11% 70% C- 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.11% 70% C- 62% D
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.07B 90% A- 90% A-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.